Agoracom Blog Home

Posts Tagged ‘CBD’

Thoughtful Brands $TBI.ca Enters into Letters of Intent to Consider Acquisitions of Golden Path and Wild Mariposa $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Posted by AGORACOM-JC at 6:02 PM on Monday, August 17th, 2020
Throught-brands-logo-small
  • Entered into letters of intent with Golden Path LLC and Wild Mariposa LLC, pursuant to which it proposes to acquire all of the outstanding membership interests in both companies
  • Golden Path and Wild Mariposa are arms-length privately held companies involved in the online marketing and distribution of consumer health products

VANCOUVER, BC /  August 17, 2020 / Thoughtful Brands Inc. (CSE:TBI)(FWB:1WZ1:GR)(OTCQB:PEMTF) (the “Company“) is pleased to announce that it has entered into letters of intent (collectively, the “Letters of Intent“), each dated August 17, 2020, with Golden Path LLC (“Golden Path“) and Wild Mariposa LLC (“Wild Mariposa“), pursuant to which it proposes to acquire all of the outstanding membership interests in both companies. Golden Path and Wild Mariposa are arms-length privately held companies involved in the online marketing and distribution of consumer health products.

Golden Path and Wild Mariposa are direct-to-consumer eCommerce brands selling a range of natural health products, including nutraceutical and hemp-based CBD products within the United States. Each product is carefully crafted based on market demand and product quality. Every product manufactured is third-party tested for purity and manufactured in the United States in GMP certified facilities. Both brands are current clients of Unified Funding, LLC which is contracted to perform a number of eCommerce business operations.

We are excited to look at the acquisition of these two established natural health brands as a further step in our eCommerce expansion in North America. Both brands possess product lines that are complimentary to Nature’s Exclusive and bring a large existing customer base along with nutraceutical product formulations and manufacturing relationships. Our timing is very strategic to acquire these brands as we near the closing of the Unified Funding asset acquisition, which will manage all go forward eCommerce operations for Thoughtful Brands”, stated Ryan Hoggan, CEO of the Company.

The Letters of Intent contemplate that the Company would acquire Golden Path, and Wild Mariposa, in consideration for the issuance of 11,544,400 common shares and 15,055,600 common shares (collectively, the “Consideration Shares“), respectively. The Consideration Shares will be issued to the existing members of Golden Path, and Wild Mariposa, at a deemed price of Cdn$0.195 per share.

The Company is at arms-length from each of Golden Path, Wild Mariposa and their respective members. The transactions contemplated by the Letters of Intent do not constitute a fundamental change for the company, nor are they expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The transactions are contingent upon each other, and the Company does not intend to proceed with the transactions unless both can be completed concurrently. Upon completion of the transactions, an administrative fee of 266,000 common shares of the Company will be owing to a consultant who assisted with the transactions.

The transactions remain subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approval and the negotiation of definitive documentation, which is expected to include warranties, representations, covenants, terms and conditions which are customary and consistent with industry standards for transactions of this nature. The transactions cannot be completed until these conditions have been satisfied.

About Thoughtful Brands Inc.

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets, and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.

ON BEHALF OF THE BOARD OF DIRECTORS

THOUGHTFUL BRANDS INC.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to its plans to acquire Golden Path and Wild Mariposa, along with additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Thoughtful Brands Inc.

Mota Ventures $MOTA.ca to Change Name to Thoughtful Brands Inc. (CSE: TBI) $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Posted by AGORACOM-JC at 7:23 PM on Wednesday, August 12th, 2020
  • Announced that it will change its name from “Mota Ventures Corp.” to “Thoughtful Brands Inc.” and its ticker symbol from “MOTA” to “TBI”
  • Subject to the approval of the Canadian Securities Exchange, the Company expects the name change to take effect on August 14, 2020

VANCOUVER, BC /  August 12, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) is pleased to announce that it will change its name from “Mota Ventures Corp.” to “Thoughtful Brands Inc.” and its ticker symbol from “MOTA” to “TBI”. Subject to the approval of the Canadian Securities Exchange (the “CSE“), the Company expects the name change to take effect on August 14, 2020 when its common shares will begin trading on the CSE under the new name and new ticker symbol.

The Company’s fundamental business continues to be the development and sale of natural health products through its eCommerce technology, with a focus on the CBD and psychedelic medicine sectors. The Company believes that the name and symbol change better reflect the success of its strategic growth and its drive to acquire and develop branded products and research initiatives in the natural health products space.

“The rebranding and new name represent our multi-faceted expansion and evolution strategies moving forward,” said CEO Ryan Dean Hoggan. “The change also reflects our commitment to becoming a global leader in the natural products industry. We are already making pivotal progress in the space through our work in psychedelics research, as well as by making quality hemp-derived CBD products more accessible worldwide through our eCommerce technology platform-and yet we are just starting to scratch the surface.”

The Company’s rebranding is the latest of several recent developments, including its:

  • European expansion through a joint venture with Franchise Cannabis Corp. whereby the Company will sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its well-established eCommerce platform. (July 2020)
  • Acquisition of Verrian, a German natural psychedelic development company with the goal of formulating treatments for addictions, including opioids and alcohol. The move propels the Company into the emerging psychedelic market and supports the Company’s forays into the natural health sector beyond the CBD market. (June 2020)

No action is required by existing shareholders with respect to the name and ticker symbol change. Certificates representing common shares of Mota Ventures Corp. will not need to be exchanged as a result of the name change. The name change was approved by the board of directors on August 10, 2020.

About Mota Ventures

Mota Ventures is an established eCommerce technology company that researches, develops, markets and sells natural health products in North America and Europe. The Company has a strong focus on the CBD market, as well as the burgeoning psychedelic medicine sector. Through its direct-to-consumer digital platform, the Company offers multiple well-established hemp-CBD brands, including Nature’s Exclusive, Sativida and Franchise. The Company also owns and operates a 110,000 square foot manufacturing facility in Radebeul, Germany, where its highly skilled team is currently conducting clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction. The Company anticipates future opportunities to create proprietary psilocybin products as legislation related to psychedelics evolves. The Company continues to pursue the acquisition of additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its powerful eCommerce technology platform.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to its plans to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Innocan $INNO.ca Engages Endless Sky to Manufacture and Distribute Innocan’s CBD Cosmetic Products in Canada $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:09 PM on Tuesday, August 11th, 2020
Innocan-Blog
  • Entered into a manufacturing and distribution agreement with Endless Sky Incorporated, a Canadian large scale Cannabis extractor based in Calgary, Alberta
  • Under the Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan.
  • ESI’s manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream.

Herzliya, Israel and Calgary, Alberta – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel”) has entered into a manufacturing and distribution agreement (the “Agreement”) with Endless Sky Incorporated (“ESI”), a Canadian large scale Cannabis extractor based in Calgary, Alberta.

Under the Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief and Go CBD Spray and Cream and the SHIR Eye Serum, Face Cream and Night Cream. The Agreement conditional upon ESI receiving Health Canada’s approval no later than December 31, 2020. According to the agreement, ESI shall pay Innocan Israel a cash license fee per Product as well as royalties based on net sales of the Products by ESI.

The Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months each based on ESI achieving minimum sales targets for the previous 12 months period.

ESI is responsible for meeting all Canadian regulations and registrations.

“Endless Sky is thrilled to exclusively manufacture and distribute Innocan’s SHIR Beauty & Science skin care line as well their Relief & Go topical products in Canada, with the future potential to access additional countries where cannabis regulations permit, and terms agreed by the parties. We believe that Innocan’s patent-pending, CBD-integrated products will be some of the highest quality CBD products to enter the market to date. Israel is well known as the global leader in CBD research and Innocan is leveraging that knowledge with a team of proven experts in the cosmetics, healthcare, sports medicine, and wellness markets. Innocan’s diligent commitment to research and development and its visionary thinking has positioned both companies to be market leaders in the CBD consumer packaged goods products space. The pharmaceutical expertise of Innocan together with Endless Sky’s large extraction capacity and manufacturing capabilities will combine to bring top of the line products to market at scale and price points that will allow for wide market access. This Agreement also positions both companies for CBD deregulation, allowing Endless Sky and Innocan’s CBD products to be further scaled through national retailers at such time. We are very excited to bring these products into the Canadian market in the very near future,” says CEO of Endless Sky, Travis George.

Iris Bincovich, Innocan’s Founder and CEO, commented: “We are thrilled to have found the right party to distribute and manufacture our CBD line of products in Canada. Distributing our CBD line of products is a significant milestone for us, given the importance of Canada to the world of CBD. Collaboration with Endless Sky, one of Canada’s largest extracting companies, will allow us to enter Innocan’s revolutionary wellness brands into the Canadian market”.

About Endless Sky Incorporated:

Endless Sky Incorporated is a Canadian large scale cannabis C02 extractor focusing on Cannabinoids. Endless Sky has a Health Canada standard processing licence which allows production of consumer packaged goods with Cannabinoids as an additive.

With top of market throughput, hemp genetics breeding program, strict QA/QC standards, and EU GMP design, Endless Sky is poised to be a global leader in low cost premium active pharmaceutical ingredients for the health, wellness and beauty markets.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Empower $CBDT.ca #Covid19 Testing Growth Adds to Revenue Diversification with Record July 2020 Patient Visits and Record Revenue Per Patient $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:18 AM on Tuesday, August 11th, 2020
  • Empower July 2020 patient volume surpasses 2,300 patients with Sun Valley Health increasing revenue per patient by 29%,
  • Adds 426 COVID-19 patient tests in July 2020 pilot testing program

VANCOUVER, BC / AUGUST 11, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a life sciences company, is pleased to announce the Company continues to execute on its plan to diversify revenue sources with 2,317 patient visits in July 2020 with record revenues coming from medical cannabis certifications, naturopathic consultations, product sales, identification card production and COVID-19 testing services.

“Diversification of revenue sources utilizing the strength of our clinic, physician, technology and operational assets has been a mission of ours.” said Steven McAuley, Chairman & CEO of Empower. “To see our team, deliver record performance in such a challenging environment, validates our execution strategy, validates the daily commitment of our team members and demonstrates we are on the right path to delivering significant shareholder value.”

The Arizona Department of Health Services announced yesterday its Phased Reopening Plan for Paused Industries indicating that community spread remains: Substantial based on the status of three main criteria: 1) Cases per 100,000 individuals: Substantial, 2) Percent positivity: Substantial, and 3) Hospital visits for COVID-like illnesses in the region: Substantial.

A dashboard available at azhealth.gov/businessCOVID19 indicates whether counties meet the recommended benchmarks for reopening of gyms, movie theaters, waterparks, tubing venues, and bars.

Further information is available at:

https://www.azdhs.gov/director/public-information-office/index.php#news-release-081020

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company conducts COVID-19 testing in its clinics under a four-phase national launch in the United States.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empowers patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Hollister Biosciences $HOLL.ca Closes $1.5 Million Private Placement Financing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:11 PM on Monday, August 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced non-brokered private placement financing by issuance of 17,646,889 units at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000

VANCOUVER, BC, Aug. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, is pleased to announce that it has closed its previously announced non-brokered private placement financing by issuance of 17,646,889 units (the “Units” and each individually, a “Unit“) at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000 (the “Offering“).  

Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant. Each warrant will be exercisable into Share at a price of $0.10 until August 10, 2022.

The Company has paid eligible finders cash commission in the total amount of $108,201.26. The Company has also issued non-transferable compensation options (“Finder’s Options“) to finders to acquire up to a total of 1,272,959 Units (“Finder’s Units“), at a price of $0.085 per Finder’s Unit on or before August 10, 2022. Each Finder’s Unit will consist of one Share and one non-transferable share purchase warrant (the “Finder’s Warrant“). Each Finder’s Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share on or before August 10, 2022.

All securities issued in connection with the Offering are subject to a statutory hold period of four-months and one day ending on December 11, 2020. The Company intends to use the net proceeds of the Offering for the expansion of Venom Extracts, Hollister’s 100% owned subsidiary, into California and for working capital and general corporate purposes.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The securities issued in connection with the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

The Real Promise of LSD, MDMA and Mushrooms for Medical Science SPONSOR: MOTA Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca

Posted by AGORACOM at 11:47 AM on Monday, August 10th, 2020

SPONSOR: Mota Ventures Corp is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Mota is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. Click Here for More Info

  • Psychedelic science is making a comeback.

Scientific publications, therapeutic breakthroughs and cultural endorsements suggest that the historical reputation of psychedelics — such as lysergic acid diethylamide (LSD), mescaline (from the peyote cactus) and psilocybin (mushrooms) — as dangerous or inherently risky have unfairly overshadowed a more optimistic interpretation. Recent publications, like Michael Pollan’s How to Change your Mind, showcase the creative and potentially therapeutic benefits that psychedelics have to offer — for mental health challenges like depression and addiction, in palliative care settings and for personal development. 

Erika Dyck

Major scientific journals have published articles showing evidence-based reasons for supporting research in psychedelic studies. These include evidence that pscilocybin significantly reduces anxiety in patients with life-threatening illnesses like cancer, that MDMA (3,4-methylenedioxy-methamphetaminecan; also known as ecstasy) improves outcomes for people suffering from PTSD and that psychedelics can produce sustained feelings of openness that are both therapeutic and personally enriching

Other researchers are investigating the traditional uses of plant medicines, such as ayahuasca, and exploring the neurological and psychotherapeutic benefits of combining Indigenous knowledge with modern medicine.

I am a medical historian, exploring why we now think that psychedelics may have a valuable role to play in human psychology, and why over 50 years ago, during the heyday of psychedelic research, we rejected that hypothesis. What has changed? What did we miss before? Is this merely a flashback?

Healing trauma, anxiety, depression

In 1957, the word psychedelic officially entered the English lexicon, introduced by British-trained and Canadian-based psychiatrist Humphry Osmond

Osmond studied mescaline from the peyote cactus, synthesized by German scientists in the 1930s, and LSD, a laboratory-produced substance created by Albert Hofmann at Sandoz in Switzerland. During the 1950s and into the 1960s, more than 1,000 scientific articles appeared as researchers around the world interrogated the potential of these psychedelics for healing addictions and trauma.

But, by the end of the 1960s, most legitimate psychedelic research ground to a halt. Some of the research had been deemed unethical, namely mind-control experiments conducted under the auspices of the CIA. Other researchers had been discredited for either unethical or self-aggrandizing use of psychedelics, or both.

Timothy Leary was perhaps the most notorious character in that regard. Having been dismissed from Harvard University, he launched a recreational career as a self-appointed apostle of psychedelic living. 
Drug regulators struggled to balance a desire for scientific research with a growing appetite for recreational use, and some argued abuse, of psychedelics.

In the popular media, these drugs came to symbolize hedonism and violence. In the United States, the government sponsored films aimed at scaring viewers about the long-term and even deadly consequences of taking LSD. Scientists were hard-pressed to maintain their credibility as popular attitudes began to shift.

Now that interpretation is beginning to change.

https://news.usask.ca/articles/research/2018/the-real-promise-of-lsd,-mdma-and-mushrooms-for-medical-science.php

Innocan’s $INNO.ca SHIR (TM) Beauty & Science #CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union $GWPH $CRDL.ca $PCLO.ca

Posted by AGORACOM-JC at 4:45 PM on Thursday, August 6th, 2020
Innocan-Blog
  • Announced that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union
  • SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results
  • The SHIR™ Beauty & science products that are approved for marketing in the Europe are: SHIR CBD+ ANTI-AGING Beauty Sleeping Mask ,SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, SHIR CBD+ ANTI-AGING Facial Serum

Herzliya, Israel and Calgary, Alberta–(August 6, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union.

SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results. The SHIR™ Beauty & science products that are approved for marketing in the Europe are: SHIR CBD+ ANTI-AGING Beauty Sleeping Mask ,SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, SHIR CBD+ ANTI-AGING Facial Serum.

Innocan’s SHIR™ Beauty & Science CBD Derma Cosmetics

https://orders.newsfilecorp.com/files/6922/61225_6b37fecc040dc9bd_002full.jpg



To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/61225_6b37fecc040dc9bd_002full.jpg

“As a Pharma Company, Innocan is committed to creating premium products that meet the highest quality standards to provide consumer confidence,” Iris Bincovich, co-founder and CEO of Innocan states. “Compliance with EU regulation is a major milestone for us, following the receipt of technical validation from the FDA for the marketing in the US of our over-the-counter Relief & Go Pain Relief spray, a few weeks ago. The next step is to initiate our various distribution platforms to deliver our SHIR™ CBD Derma Cosmetic line across the European Union and other markets where legally permitted to do so.”

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Hollister Biosciences Inc. $HOLL.ca and Heavy Brands Inc. Enter into Letter of Intent for Proposed Joint Venture Agreement $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:16 AM on Wednesday, August 5th, 2020
  • Announced that it’s entered into a letter of intent to manufacture pre-rolls for some of the biggest names in rock and metal music
  • Under the terms of the Agreement, Heavy intends to license its Heavy Grass brand for use by Hollister in connection with branding, production and sale of cannabis products primarily via collaborations with its roster of music artists
  • Hollister will grant to Heavy a limited license for use of its HashBone brand for incorporation into any packaging and/or logo design of products. Heavy will retain ownership of all co-brand designs

VANCOUVER, BC, Aug. 5, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company”, “Hollister Cannabis Co.” or “Hollister”) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona, is pleased to announce that it has entered into a letter of intent (the “LOI”) to complete a Definitive Agreement (the “Agreement”) with Heavy Brands Inc. (“Heavy”), a rock and heavy metal lifestyle cannabis branding company.

Under the terms of the Agreement, Heavy intends to license its Heavy Grass brand for use by Hollister in connection with branding, production and sale of cannabis products primarily via collaborations with its roster of music artists. Hollister will grant to Heavy a limited license for use of its HashBone brand for incorporation into any packaging and/or logo design of products. Heavy will retain ownership of all co-brand designs.

Products will be introduced in time and will include separate product branding. Heavy will lead the marketing initiatives of the new products leveraging their unique access to the live music industry.  

Heavy-Hollister co-brand products will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc. (CSE: INDS), with the first product anticipated to be ready for distribution by October 1, 2020.

When asked about the Agreement, Dez Mitchell, head of Product Development from Heavy shared: “We are so thrilled to begin our partnership with Hollister and cannot wait to launch our first products together this fall.  For our Heavy Grass family, music and cannabis go hand in hand.  We have been fortunate to get to know Carl and his team over the last year and they have proven to uniquely understand our vision.  We are excited to show the world what we’ve been working on together.”

CEO of Hollister Biosciences, Carl Saling, also shared: “Music and cannabis have gone together for so many years; and lately, for the most part, it’s been all connected to rap and hip hop. I have always wanted to bring more attention to cannabis and connect with fans of heavy metal in a truly authentic way.

We have big things in store for our initial launch, and looking forward to many awesome rock and metal collaborations that Hollister and Heavy Grass will be bringing to market.”

About Heavy Brands

Heavy Brands Inc. is a Southern California lifestyle cannabis branding and marketing company building globally recognized cannabis lifestyle brands based in Los Angeles.  It’s flagship brand, Heavy Grass, has grown organically by connecting hard rock and heavy metal fans to cannabis products that speak to their lifestyle.  Additionally, Heavy Grass releases a seasonal line of apparel that is worn by some of the largest rock artists and fans around the world.

Website: https://getheavy.com/

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

VIDEO – Empower Clinics $CBDT.ca Grows Revenue 416% To $USD 790,000 In Q1 – BEFORE COVID-19 Revenues Commenced In Q2 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 5:36 PM on Wednesday, July 29th, 2020

Sometimes, you just have to let the numbers speak for themselves.  With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for …

but then these numbers came in for:   2019 – Year Ended DEC 31, 2019 Q4 – Quarter Ended DEC 31, 2019 Q1 – Quarter Ended MAR 31, 2020  

Patient Visits

  • 2019 +110% To 15,900
  • Q4 + 251% To 4,616
  • Q1 + 377% To 5,717 (PRE COVID REVENUES COMMENCING Q2)

Revenues $USD

  • 2019 + 86% To $2.03M
  • Q4 + 217% To $625,000
  • Q1 + 416% To $790,000  (PRE COVID REVENUES COMMENCING Q2)  

Do you see a trend?   

We can’t wait for Q2 numbers (April, May, June) because we already know patient visits for April alone were up over 870%.   

Looking even further forward into Q3 (July, August, September), we already know that July patient visits are going to set a record.    

Though CBDT had a very short cease trade order due to the delay in getting these financials filed…. the wait was clearly worth it, as was this interview with CEO, Steven McAuley,  who is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.  

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Spyder Cannabis $SPDR.ca Announces Final Approvals to Open Niagara Falls and Calgary Cannabis Dispensaries $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:40 AM on Wednesday, July 29th, 2020
  • Announced that its dispensary located at 6474 Lundy’s Lane, passed its final inspection on July 27, 2020, and intends to open for business in the first week of August 2020
  • Also announced that its dispensary located at #140, 104 – 58 Avenue SE, was formally issued a Retail Cannabis Store License (No. 781144-1) and intends to open for business in August 2020

Vaughan, Ontario–(July 29, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to provide the following update:

Niagara Falls and Cannabis Dispensary

The Company is pleased to announce that its dispensary located at 6474 Lundy’s Lane, passed its final inspection on July 27, 2020, and intends to open for business in the first week of August 2020.

Calgary Cannabis Dispensary

The Company is also pleased to announce that its dispensary located at #140, 104 – 58 Avenue SE, was formally issued a Retail Cannabis Store License (No. 781144-1) and intends to open for business in August 2020.

“Both dispensaries are located in busy commercial hubs, in their respective cities. The Spyder team is excited to commence operations and bring its best of class customer service and retail experience to both cities”, stated Dan Pelchovitz, the Company’s CEO.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of Hemp CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain ‘forward-looking information” within the meaning of applicable securities laws (‘forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

For additional info, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]